Hub : Traits :

Fed-up feelings

640 significantly associated models · 86 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 2 23453834 25141538 4 2 3.2e-10 2.2e-10 3.0e-02 88 C2orf84 UBXN2A
2 3 48381826 51009435 21 1 5.1e-14 6.6e-13 1.9e-01 97 GPX1
3 3 135273949 137261517 4 1 7.5e-11 4.7e-10 6.2e-01 99 STAG1
4 3 149722394 151134540 1 1 4.1e-12 1.1e-05 3.7e-01 96 RP11-103G8.2
5 7 116660803 118207833 1 1 7.6e-08 5.5e-10 4.0e-04 68 CTTNBP2
6 8 8092025 11891593 12 1 6.0e-13 4.3e-11 2.3e-01 97 FAM86B3P
7 9 119768572 121177842 1 1 2.3e-07 3.3e-07 1.0e+00 100 TLR4
8 11 46010847 48285906 8 1 1.4e-11 5.7e-10 2.5e-02 87 ZNF408
9 11 63316786 64820283 2 1 1.5e-08 7.9e-08 2.5e-03 68 PPP1R14B
10 12 111154626 112582540 1 1 1.5e-07 9.7e-07 2.4e-01 94 SH2B3
11 14 74424938 76226003 5 2 2.5e-10 3.1e-11 8.3e-02 93 AREL1 DLST
12 17 42774693 45796313 19 1 5.2e-12 2.4e-11 1.0e+00 100 KANSL1-AS1
13 18 34614002 35378540 1 1 4.5e-09 2.3e-12 4.3e-05 66 CELF4
14 18 49172179 51753106 1 1 1.5e-07 6.1e-12 2.3e-06 53 DCC
15 19 32209988 33668090 2 1 3.9e-10 1.0e-09 1.0e+00 100 DPY19L3
16 20 2429222 3827309 1 1 1.7e-07 5.2e-05 2.2e-01 91 FASTKD5
17 20 44501458 44999958 1 1 1.1e-07 5.1e-07 1.0e-01 89 CD40

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder or Schizophrenia 1.65 2 0 0.0 0.00 1.0e+00 DCC FAM86B3P
Depressed Affect (Nagel 2018) 16.33 16 12 26.7 0.98 9.8e-12 AREL1 C2orf84 CD40 CELF4 DCC DLST DPY19L3 FASTKD5 GPX1 KANSL1-AS1 RP11-103G8.2 SH2B3 STAG1 TLR4 UBXN2A ZNF408
Depression (Nagel 2018) 7.47 7 1 2.2 0.99 1.1e-05 CD40 DCC DPY19L3 KANSL1-AS1 STAG1 UBXN2A ZNF408
Intelligence (Savage-Jansen 2018) 3.91 3 2 4.4 0.00 1.0e+00 GPX1 KANSL1-AS1 STAG1
Neuroticism (Nagel 2018) 13.90 15 10 22.2 0.97 4.7e-09 AREL1 CD40 CELF4 CTTNBP2 DCC DLST DPY19L3 FASTKD5 GPX1 KANSL1-AS1 RP11-103G8.2 STAG1 TLR4 UBXN2A ZNF408
Schizophrenia (2018) 2.13 2 0 0.0 0.00 1.0e+00 DCC STAG1
Schizophrenia vs Biploar Disorder 1.83 1 0 0.0 0.00 1.0e+00 KANSL1-AS1
Worry (Nagel 2018) 6.79 5 4 8.9 0.98 2.6e-03 AREL1 DLST KANSL1-AS1 STAG1 ZNF408
Crohns Disease (2017) 2.98 2 1 2.2 0.00 1.0e+00 GPX1 PPP1R14B
Irritable Bowel Disease (IBD) 3.36 1 1 2.2 0.00 1.0e+00 GPX1
Ulcerative Colitis (UC) 2.36 1 1 2.2 0.00 1.0e+00 GPX1
Major Depression (MDD) 4.18 1 0 0.0 0.00 1.0e+00 GPX1
Reaction Time 3.43 1 1 2.2 0.00 1.0e+00 SH2B3
Verbal and Numeric Reasoning (VNR) 3.26 3 1 2.2 0.00 1.0e+00 GPX1 KANSL1-AS1 STAG1
Breast Cancer 1.80 2 1 2.2 0.00 1.0e+00 GPX1 KANSL1-AS1
Ovarian Cancer 3.05 1 1 2.2 0.00 1.0e+00 KANSL1-AS1
Prostate Cancer 2.04 1 0 0.0 0.00 1.0e+00 GPX1
Age at First Birth 3.94 1 1 2.2 0.00 1.0e+00 GPX1
Coronary Artery Disease (CAD) 2.59 1 0 0.0 0.00 1.0e+00 SH2B3
Crohns Disease (2012) 2.48 1 1 2.2 0.00 1.0e+00 GPX1
HDL Cholesterol 1.85 1 0 0.0 0.00 1.0e+00 DPY19L3
LDL Cholesterol 2.00 1 0 0.0 0.00 1.0e+00 SH2B3
Lupus 2.07 1 0 0.0 0.00 1.0e+00 FAM86B3P
Neuroticism (2016) 8.46 6 2 4.4 0.98 4.0e-04 AREL1 CELF4 FAM86B3P KANSL1-AS1 TLR4 ZNF408
Primary Biliary Cirrhosis 3.11 3 1 2.2 0.00 1.0e+00 KANSL1-AS1 PPP1R14B SH2B3
Rheumatoid Arthritis 3.16 2 1 2.2 0.00 1.0e+00 CD40 SH2B3
Schizophrenia (2014) 2.37 2 0 0.0 0.00 1.0e+00 FAM86B3P STAG1
Ulcerative Colitis 2.11 1 1 2.2 0.00 1.0e+00 GPX1
Blood Eosinophil Count 10.62 2 2 4.4 0.00 1.0e+00 KANSL1-AS1 SH2B3
Blood Platelet Count 2.37 5 4 8.9 -0.76 1.3e-01 AREL1 DLST KANSL1-AS1 PPP1R14B SH2B3
Blood Red Count 4.57 4 4 8.9 -0.24 7.6e-01 C2orf84 KANSL1-AS1 SH2B3 UBXN2A
Blood White Count 6.70 7 6 13.3 -0.96 7.6e-04 C2orf84 FASTKD5 GPX1 KANSL1-AS1 RP11-103G8.2 SH2B3 UBXN2A
Heel T-Score 3.03 5 2 4.4 -0.21 7.3e-01 AREL1 DLST KANSL1-AS1 PPP1R14B ZNF408
BMI 1.78 4 1 2.2 0.66 3.4e-01 DPY19L3 GPX1 PPP1R14B TLR4
Height 1.48 10 8 17.8 -0.54 1.1e-01 AREL1 C2orf84 CD40 CTTNBP2 DCC GPX1 KANSL1-AS1 SH2B3 STAG1 UBXN2A
Waist Hip Ratio (WHR) 3.10 6 3 6.7 -0.10 8.6e-01 C2orf84 GPX1 KANSL1-AS1 PPP1R14B STAG1 UBXN2A
Systolic Blood Pressure 5.17 6 5 11.1 -0.68 1.4e-01 AREL1 GPX1 KANSL1-AS1 PPP1R14B SH2B3 ZNF408
Smoking Status 3.75 3 2 4.4 0.00 1.0e+00 CTTNBP2 GPX1 PPP1R14B
Allergy or Eczema 1.16 1 0 0.0 0.00 1.0e+00 CD40
Cardiovascular Disease 3.57 3 2 4.4 0.00 1.0e+00 PPP1R14B SH2B3 ZNF408
Hypothyroidism (self reported) 8.14 2 2 4.4 0.00 1.0e+00 PPP1R14B SH2B3
Type 2 Diabetes (T2D) (2018) 1.64 1 0 0.0 0.00 1.0e+00 SH2B3
Lung FEV1/FVC ratio 1.97 5 2 4.4 -0.69 1.9e-01 AREL1 CTTNBP2 DLST GPX1 KANSL1-AS1
Lung FVC 3.96 5 3 6.7 -0.59 3.0e-01 DCC GPX1 KANSL1-AS1 SH2B3 UBXN2A
Neuroticism 13.02 14 10 22.2 0.97 1.1e-08 AREL1 C2orf84 CD40 CELF4 CTTNBP2 DLST DPY19L3 FASTKD5 GPX1 KANSL1-AS1 STAG1 TLR4 UBXN2A ZNF408
Hair Pigment 0.20 2 1 2.2 0.00 1.0e+00 KANSL1-AS1 SH2B3
Tanning 0.39 2 0 0.0 0.00 1.0e+00 AREL1 SH2B3
Hand grip strength (left) 2.48 2 2 4.4 0.00 1.0e+00 AREL1 KANSL1-AS1
Number of treatments/medications taken 5.33 4 4 8.9 0.60 4.0e-01 AREL1 DLST GPX1 SH2B3
Sensitivity / hurt feelings 6.44 4 1 2.2 0.92 8.1e-02 CELF4 FAM86B3P KANSL1-AS1 STAG1
Frequency of depressed mood in last 2 weeks 9.16 5 1 2.2 0.99 1.3e-03 FAM86B3P KANSL1-AS1 STAG1 UBXN2A ZNF408
Relative age of first facial hair 3.46 1 1 2.2 0.00 1.0e+00 KANSL1-AS1
Systolic blood pressure, automated reading 4.98 6 4 8.9 -0.57 2.4e-01 AREL1 FAM86B3P GPX1 KANSL1-AS1 SH2B3 ZNF408
Medication: Co-codamol 2.54 1 0 0.0 0.00 1.0e+00 GPX1
Pack years adult smoking proportion 2.82 2 0 0.0 0.00 1.0e+00 CELF4 GPX1
Impedance of leg (right) 2.48 6 2 4.4 -0.25 6.3e-01 AREL1 FAM86B3P GPX1 KANSL1-AS1 STAG1 UBXN2A
Leg fat-free mass (left) 1.58 3 1 2.2 0.00 1.0e+00 FAM86B3P GPX1 SH2B3
Trunk fat percentage 2.52 6 3 6.7 0.61 2.0e-01 AREL1 C2orf84 DPY19L3 GPX1 KANSL1-AS1 UBXN2A
Hand grip strength (right) 1.76 1 1 2.2 0.00 1.0e+00 KANSL1-AS1
Townsend deprivation index at recruitment 2.40 1 0 0.0 0.00 1.0e+00 CTTNBP2
Current tobacco smoking 3.23 2 0 0.0 0.00 1.0e+00 CELF4 CTTNBP2
Frequency of unenthusiasm / disinterest in last 2 weeks 7.60 4 0 0.0 0.98 1.5e-02 DCC GPX1 STAG1 UBXN2A
Relative age voice broke 2.69 1 1 2.2 0.00 1.0e+00 KANSL1-AS1
Taking other prescription medications 5.62 5 3 6.7 0.58 3.1e-01 AREL1 DLST GPX1 PPP1R14B SH2B3
Age when periods started (menarche) 1.87 1 1 2.2 0.00 1.0e+00 GPX1
Heel bone mineral density (BMD) T-score, automated (left) 3.79 2 2 4.4 0.00 1.0e+00 FAM86B3P ZNF408
Qualifications: CSEs or equivalent 1.57 1 0 0.0 0.00 1.0e+00 GPX1
High blood pressure 4.11 3 3 6.7 0.00 1.0e+00 FAM86B3P SH2B3 ZNF408
Stomach or abdominal pain in last month 2.56 1 0 0.0 0.00 1.0e+00 STAG1
Medication: Atenolol 2.84 1 1 2.2 0.00 1.0e+00 SH2B3
Medication: Levothyroxine sodium 7.31 3 2 4.4 0.00 1.0e+00 FAM86B3P PPP1R14B SH2B3
Sitting height 2.66 5 4 8.9 -0.81 9.5e-02 C2orf84 DCC KANSL1-AS1 UBXN2A ZNF408
Body mass index (BMI) 3.02 4 3 6.7 0.46 5.4e-01 DPY19L3 FAM86B3P GPX1 STAG1
Impedance of leg (left) 2.58 6 4 8.9 -0.23 6.5e-01 AREL1 FAM86B3P GPX1 KANSL1-AS1 STAG1 UBXN2A
Leg predicted mass (left) 1.61 3 1 2.2 0.00 1.0e+00 FAM86B3P GPX1 SH2B3
Trunk fat mass 2.05 3 2 4.4 0.00 1.0e+00 DPY19L3 GPX1 KANSL1-AS1
Waist circumference 1.80 2 2 4.4 0.00 1.0e+00 DPY19L3 GPX1
Past tobacco smoking 3.26 2 0 0.0 0.00 1.0e+00 CTTNBP2 SH2B3
Alcohol usually taken with meals 3.52 2 2 4.4 0.00 1.0e+00 CELF4 CTTNBP2
Nervous feelings 6.17 6 3 6.7 0.99 3.3e-04 AREL1 DLST FAM86B3P KANSL1-AS1 STAG1 ZNF408
Frequency of tenseness / restlessness in last 2 weeks 7.92 5 3 6.7 0.98 4.2e-03 GPX1 KANSL1-AS1 STAG1 UBXN2A ZNF408
Hearing difficulty/problems with background noise 2.35 2 0 0.0 0.00 1.0e+00 KANSL1-AS1 ZNF408
Hair/balding pattern: Pattern 2 1.79 1 0 0.0 0.00 1.0e+00 KANSL1-AS1
Forced vital capacity (FVC) 3.43 2 2 4.4 0.00 1.0e+00 GPX1 KANSL1-AS1
Heel bone mineral density (BMD) T-score, automated (right) 4.23 2 2 4.4 0.00 1.0e+00 FAM86B3P ZNF408
Ever unenthusiastic/disinterested for a whole week 4.05 1 0 0.0 0.00 1.0e+00 KANSL1-AS1
Qualifications: None of the above 4.14 2 1 2.2 0.00 1.0e+00 CELF4 GPX1
Heart attack 1.77 1 0 0.0 0.00 1.0e+00 SH2B3
Pain all over the body in last month 1.97 1 0 0.0 0.00 1.0e+00 GPX1
Fluid intelligence score 2.82 2 2 4.4 0.00 1.0e+00 GPX1 STAG1
Illnesses of siblings 2.22 1 0 0.0 0.00 1.0e+00 SH2B3
Neuroticism score 14.47 14 9 20.0 0.98 3.3e-09 AREL1 C2orf84 CD40 CELF4 CTTNBP2 DLST DPY19L3 FAM86B3P GPX1 KANSL1-AS1 STAG1 TLR4 UBXN2A ZNF408
Weight 1.74 4 1 2.2 0.57 4.3e-01 DPY19L3 FAM86B3P GPX1 SH2B3
Impedance of arm (right) 3.47 4 4 8.9 -0.53 4.7e-01 FAM86B3P GPX1 KANSL1-AS1 STAG1
Arm fat percentage (right) 2.25 3 2 4.4 0.00 1.0e+00 DPY19L3 FAM86B3P GPX1
Trunk fat-free mass 1.91 5 1 2.2 0.49 4.0e-01 CD40 GPX1 SH2B3 UBXN2A ZNF408
Hip circumference 1.96 5 2 4.4 0.41 4.9e-01 DPY19L3 FAM86B3P GPX1 PPP1R14B SH2B3
Alcohol intake versus 10 years previously 2.77 1 0 0.0 0.00 1.0e+00 GPX1
Father's age at death 4.57 2 1 2.2 0.00 1.0e+00 GPX1 SH2B3
Worrier / anxious feelings 8.08 6 5 11.1 0.99 1.3e-04 AREL1 DLST FAM86B3P KANSL1-AS1 STAG1 TLR4
Frequency of tiredness / lethargy in last 2 weeks 7.31 5 1 2.2 0.98 3.4e-03 DCC GPX1 STAG1 UBXN2A ZNF408
Hair/balding pattern: Pattern 3 3.58 1 1 2.2 0.00 1.0e+00 KANSL1-AS1
Number of live births 1.70 1 0 0.0 0.00 1.0e+00 KANSL1-AS1
Forced expiratory volume in 1-second (FEV1) 4.37 5 2 4.4 0.09 8.8e-01 C2orf84 FAM86B3P GPX1 KANSL1-AS1 UBXN2A
Qualifications: A levels/AS levels or equivalent 4.87 2 1 2.2 0.00 1.0e+00 GPX1 KANSL1-AS1
Mouth/teeth dental problems: Dentures 2.48 2 0 0.0 0.00 1.0e+00 GPX1 STAG1
Medication: Ibuprofen (e.g. Nurofen) 2.92 2 0 0.0 0.00 1.0e+00 KANSL1-AS1 UBXN2A
Forced expiratory volume in 1-second (FEV1), Best measure 3.94 3 2 4.4 0.00 1.0e+00 GPX1 KANSL1-AS1 ZNF408
Impedance of arm (left) 3.74 5 4 8.9 -0.61 2.8e-01 FAM86B3P GPX1 KANSL1-AS1 SH2B3 STAG1
Arm fat mass (right) 2.31 3 3 6.7 0.00 1.0e+00 DPY19L3 FAM86B3P GPX1
Trunk predicted mass 1.90 5 1 2.2 0.51 3.9e-01 CD40 GPX1 SH2B3 UBXN2A ZNF408
Standing height 1.49 8 3 6.7 -0.41 3.1e-01 C2orf84 FAM86B3P GPX1 KANSL1-AS1 SH2B3 STAG1 UBXN2A ZNF408
Exposure to tobacco smoke at home 2.30 1 0 0.0 0.00 1.0e+00 GPX1
Tense / 'highly strung' 4.24 2 1 2.2 0.00 1.0e+00 AREL1 FAM86B3P
Seen doctor (GP) for nerves, anxiety, tension or depression 4.66 4 0 0.0 1.00 4.4e-03 AREL1 CELF4 CTTNBP2 ZNF408
Hair/balding pattern: Pattern 4 5.97 1 1 2.2 0.00 1.0e+00 KANSL1-AS1
Birth weight of first child 2.49 1 1 2.2 0.00 1.0e+00 SH2B3
Peak expiratory flow (PEF) 2.55 2 1 2.2 0.00 1.0e+00 FAM86B3P KANSL1-AS1
Ever highly irritable/argumentative for 2 days 3.52 1 0 0.0 0.00 1.0e+00 GPX1
Qualifications: O levels/GCSEs or equivalent 2.74 1 0 0.0 0.00 1.0e+00 GPX1
Medication: Paracetamol 4.30 2 1 2.2 0.00 1.0e+00 GPX1 KANSL1-AS1
Headache pain in last month 4.41 2 1 2.2 0.00 1.0e+00 KANSL1-AS1 TLR4
Medication for cholesterol, blood pressure or diabetes 2.39 1 1 2.2 0.00 1.0e+00 SH2B3
Gout (self-reported) 2.22 2 0 0.0 0.00 1.0e+00 PPP1R14B SH2B3
Hypothyroidism/myxoedema (self-reported) 7.79 3 2 4.4 0.00 1.0e+00 FAM86B3P PPP1R14B SH2B3
Birth weight 1.61 1 1 2.2 0.00 1.0e+00 SH2B3
High blood pressure (siblings) 1.78 1 0 0.0 0.00 1.0e+00 SH2B3
Forced vital capacity (FVC), Best measure 3.40 3 2 4.4 0.00 1.0e+00 GPX1 KANSL1-AS1 ZNF408
Body fat percentage 2.76 5 3 6.7 0.99 6.1e-04 AREL1 C2orf84 DPY19L3 GPX1 UBXN2A
Leg fat percentage (right) 3.81 6 3 6.7 0.61 2.0e-01 AREL1 C2orf84 DPY19L3 FAM86B3P GPX1 UBXN2A
Arm fat-free mass (right) 1.88 3 2 4.4 0.00 1.0e+00 FAM86B3P GPX1 SH2B3
Exposure to tobacco smoke outside home 4.22 1 1 2.2 0.00 1.0e+00 CTTNBP2
Comparative body size at age 10 1.42 1 1 2.2 0.00 1.0e+00 FAM86B3P
Number of full brothers 2.53 1 0 0.0 0.00 1.0e+00 GPX1
Worry too long after embarrassment 4.73 3 2 4.4 0.00 1.0e+00 FAM86B3P KANSL1-AS1 STAG1
Wheeze or whistling in the chest in last year 2.79 1 0 0.0 0.00 1.0e+00 GPX1
Age at first live birth 4.39 2 1 2.2 0.00 1.0e+00 CELF4 GPX1
Health satisfaction 2.55 1 0 0.0 0.00 1.0e+00 GPX1
Qualifications: College or University degree 5.54 5 3 6.7 -0.92 2.7e-02 CELF4 CTTNBP2 GPX1 KANSL1-AS1 PPP1R14B
Medication for pain relief, constipation, heartburn 4.60 3 1 2.2 0.00 1.0e+00 AREL1 GPX1 KANSL1-AS1
Neck or shoulder pain in last month 2.13 1 0 0.0 0.00 1.0e+00 GPX1
Medication: Blood pressure 3.19 1 1 2.2 0.00 1.0e+00 SH2B3
Medication: Allopurinol 2.09 2 0 0.0 0.00 1.0e+00 PPP1R14B SH2B3
Mean time to correctly identify matches 3.51 2 1 2.2 0.00 1.0e+00 SH2B3 ZNF408
Whole body fat mass 2.29 3 2 4.4 0.00 1.0e+00 DPY19L3 FAM86B3P GPX1
Leg fat mass (right) 2.86 3 3 6.7 0.00 1.0e+00 DPY19L3 FAM86B3P GPX1
Arm predicted mass (right) 1.99 3 3 6.7 0.00 1.0e+00 FAM86B3P GPX1 SH2B3
Alcohol intake frequency. 2.67 2 1 2.2 0.00 1.0e+00 DCC KANSL1-AS1
Comparative height size at age 10 2.00 4 3 6.7 -0.58 4.2e-01 DLST KANSL1-AS1 SH2B3 STAG1
Suffer from 'nerves' 5.46 4 2 4.4 1.00 7.8e-04 AREL1 DLST FAM86B3P ZNF408
Overall health rating 4.18 2 1 2.2 0.00 1.0e+00 GPX1 ZNF408
Age at last live birth 3.18 1 1 2.2 0.00 1.0e+00 GPX1
Leg pain on walking 2.84 1 0 0.0 0.00 1.0e+00 GPX1
Illness, injury, bereavement, stress in last 2 years 2.32 1 0 0.0 0.00 1.0e+00 CTTNBP2
Medication: Aspirin 2.53 1 0 0.0 0.00 1.0e+00 SH2B3
Hypertension (Self-reported) 3.95 3 3 6.7 0.00 1.0e+00 FAM86B3P SH2B3 ZNF408
Smoking status: Previous 2.77 1 0 0.0 0.00 1.0e+00 SH2B3
Whole body fat-free mass 1.81 5 2 4.4 0.43 4.7e-01 FAM86B3P GPX1 SH2B3 UBXN2A ZNF408
Leg fat-free mass (right) 1.62 3 1 2.2 0.00 1.0e+00 FAM86B3P GPX1 SH2B3
Arm fat percentage (left) 2.33 3 2 4.4 0.00 1.0e+00 DPY19L3 FAM86B3P GPX1
Handedness (chirality/laterality): Left-handed 1.76 1 0 0.0 0.00 1.0e+00 KANSL1-AS1
Mood swings 13.18 13 5 11.1 0.98 1.9e-09 AREL1 CD40 CELF4 CTTNBP2 DCC DLST DPY19L3 FAM86B3P GPX1 KANSL1-AS1 STAG1 TLR4 ZNF408
Loneliness, isolation 7.55 5 0 0.0 1.00 1.1e-04 GPX1 KANSL1-AS1 SH2B3 STAG1 ZNF408
Qualifications: nursing, teaching 3.46 1 0 0.0 0.00 1.0e+00 GPX1
Mouth/teeth dental problems: Mouth ulcers 2.95 2 1 2.2 0.00 1.0e+00 KANSL1-AS1 SH2B3
Medication for cholesterol 3.24 1 1 2.2 0.00 1.0e+00 SH2B3
Illnesses of father: None of the above (group 1) 1.74 1 0 0.0 0.00 1.0e+00 SH2B3
Smoking status: Current 2.98 1 0 0.0 0.00 1.0e+00 CTTNBP2
Forced expiratory volume in 1-second (FEV1), predicted percentage 2.55 1 1 2.2 0.00 1.0e+00 KANSL1-AS1
Whole body water mass 1.84 5 2 4.4 0.44 4.6e-01 FAM86B3P GPX1 SH2B3 UBXN2A ZNF408
Leg predicted mass (right) 1.63 4 1 2.2 0.30 7.0e-01 FAM86B3P GPX1 SH2B3 ZNF408
Arm fat mass (left) 2.23 3 3 6.7 0.00 1.0e+00 DPY19L3 FAM86B3P GPX1
Number of self-reported non-cancer illnesses 4.19 4 1 2.2 -0.99 8.5e-03 AREL1 PPP1R14B SH2B3 ZNF408
Average weekly champagne plus white wine intake 2.57 1 0 0.0 0.00 1.0e+00 KANSL1-AS1
Miserableness 12.19 12 6 13.3 0.99 3.0e-10 C2orf84 CD40 CELF4 CTTNBP2 DPY19L3 FAM86B3P GPX1 KANSL1-AS1 RP11-103G8.2 STAG1 UBXN2A ZNF408
Guilty feelings 9.89 7 4 8.9 0.95 9.4e-04 AREL1 C2orf84 DLST FAM86B3P GPX1 KANSL1-AS1 UBXN2A
Financial situation satisfaction 3.19 1 1 2.2 0.00 1.0e+00 GPX1
Medication: Blood pressure 3.97 3 1 2.2 0.00 1.0e+00 KANSL1-AS1 SH2B3 ZNF408
Medication: Bendroflumethiazide 3.04 2 0 0.0 0.00 1.0e+00 FAM86B3P SH2B3
Medication: Paracetamol 4.28 2 1 2.2 0.00 1.0e+00 GPX1 KANSL1-AS1
Medication: Lisinopril 2.25 1 0 0.0 0.00 1.0e+00 ZNF408
Illnesses of father: High blood pressure 1.71 1 0 0.0 0.00 1.0e+00 SH2B3
Ever smoked 3.46 2 1 2.2 0.00 1.0e+00 CTTNBP2 SH2B3
Basal metabolic rate 1.74 4 2 4.4 0.57 4.3e-01 DPY19L3 FAM86B3P GPX1 SH2B3
Leg fat percentage (left) 3.76 6 3 6.7 0.60 2.1e-01 AREL1 C2orf84 DPY19L3 FAM86B3P GPX1 UBXN2A
Arm fat-free mass (left) 2.08 4 2 4.4 0.61 3.9e-01 DPY19L3 FAM86B3P GPX1 SH2B3
Average weekly beer plus cider intake 3.50 2 0 0.0 0.00 1.0e+00 CELF4 FAM86B3P
Irritability 6.69 5 2 4.4 0.99 1.6e-03 AREL1 CELF4 FAM86B3P KANSL1-AS1 TLR4
Age started oral contraceptive pill 2.11 1 0 0.0 0.00 1.0e+00 GPX1
Diastolic blood pressure, automated reading 5.80 4 3 6.7 -0.70 3.0e-01 FAM86B3P GPX1 SH2B3 ZNF408
Vascular/heart problems diagnosed by doctor 3.99 3 2 4.4 0.00 1.0e+00 FAM86B3P SH2B3 ZNF408
Pain experienced in last month 3.84 2 1 2.2 0.00 1.0e+00 GPX1 KANSL1-AS1
Heart attack/myocardial infarction (self-reported) 1.80 1 0 0.0 0.00 1.0e+00 SH2B3
Pack years of smoking 2.48 2 0 0.0 0.00 1.0e+00 CELF4 GPX1
Impedance of whole body 3.40 6 4 8.9 -0.36 4.9e-01 AREL1 FAM86B3P GPX1 KANSL1-AS1 STAG1 UBXN2A
Leg fat mass (left) 2.84 3 3 6.7 0.00 1.0e+00 DPY19L3 FAM86B3P GPX1
Arm predicted mass (left) 2.05 4 2 4.4 0.61 3.9e-01 CD40 FAM86B3P GPX1 SH2B3

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 12 0.344 1.9
GTEx Adipose Visceral Omentum 11 0.540 2.0
GTEx Adrenal Gland 8 0.549 1.9
GTEx Artery Aorta 13 0.437 1.9
GTEx Artery Coronary 11 0.930 2.1
GTEx Artery Tibial 14 0.372 1.9
GTEx Brain Caudate basal ganglia 7 0.761 2.0
GTEx Brain Cerebellar Hemisphere 11 0.739 1.9
GTEx Brain Cerebellum 12 0.605 1.9
GTEx Brain Cortex 8 0.773 2.0
GTEx Brain Frontal Cortex BA9 8 0.866 2.1
GTEx Brain Hippocampus 4 0.763 2.0
GTEx Brain Hypothalamus 6 1.017 2.0
GTEx Brain Nucleus accumbens basal ganglia 7 0.809 1.9
GTEx Brain Putamen basal ganglia 6 0.962 2.0
GTEx Breast Mammary Tissue 9 0.456 2.0
GTEx Breast Mammary Tissue (Male) 7 0.587 1.8
GTEx Breast Mammary Tissue (Female) 9 0.547 1.9
GTEx Cells EBV-transformed lymphocytes 9 0.632 2.0
GTEx Cells Transformed fibroblasts 17 0.405 1.9
GTEx Colon Sigmoid 12 0.821 2.0
GTEx Colon Transverse 14 0.678 1.9
GTEx Esophagus Gastroesophageal Junction 9 0.623 2.0
GTEx Esophagus Mucosa 18 0.542 1.9
GTEx Esophagus Muscularis 21 0.650 2.0
GTEx Heart Atrial Appendage 11 0.697 1.9
GTEx Heart Left Ventricle 9 0.588 2.0
GTEx Liver 4 0.558 1.8
GTEx Lung 17 0.592 1.9
GTEx Muscle Skeletal 10 0.346 1.9
GTEx Nerve Tibial 12 0.278 1.9
GTEx Ovary 7 0.771 2.1
GTEx Pancreas 9 0.551 1.9
GTEx Pituitary 7 0.628 1.9
GTEx Prostate 8 0.958 2.2
GTEx Skin Not Sun Exposed Suprapubic 14 0.569 2.1
GTEx Skin Sun Exposed Lower leg 16 0.440 2.0
GTEx Small Intestine Terminal Ileum 5 1.085 2.1
GTEx Spleen 10 0.709 2.0
GTEx Stomach 11 0.757 2.0
GTEx Testis 16 0.507 1.9
GTEx Thyroid 15 0.375 1.9
GTEx Uterus 8 1.411 2.3
GTEx Vagina 7 1.102 2.1
GTEx Whole Blood 6 0.301 1.8
METSIM Adipose 4 0.087 1.6
NTR Blood 7 0.291 1.7
ROSMAP Brain Pre-frontal Cortex 15 0.342 1.9
YFS Blood 4 0.087 1.6
CommonMind Brain Pre-frontal Cortex 12 0.223 1.7
The Cancer Genome Atlas Bladder Urothelial Carcinoma 3 0.181 1.7
The Cancer Genome Atlas Breast Invasive Carcinoma 6 0.136 1.7
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 4 0.365 1.8
The Cancer Genome Atlas Colon Adenocarcinoma 3 0.145 1.8
The Cancer Genome Atlas Esophageal Carcinoma 6 0.876 2.0
The Cancer Genome Atlas Glioblastoma Multiforme 4 0.391 1.7
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 9 0.331 1.8
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 7 0.171 1.6
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 6 0.293 1.8
The Cancer Genome Atlas Brain Lower Grade Glioma 9 0.209 1.7
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 3 0.271 1.7
The Cancer Genome Atlas Lung Adenocarcinoma 13 0.442 1.7
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 8 0.319 1.8
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 6 0.377 1.7
The Cancer Genome Atlas Pancreatic Adenocarcinoma 6 0.361 1.7
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 5 0.377 1.8
The Cancer Genome Atlas Prostate Adenocarcinoma 10 0.216 1.7
The Cancer Genome Atlas Rectum Adenocarcinoma 3 0.434 1.8
The Cancer Genome Atlas Soft Tissue Sarcoma 3 0.281 1.8
The Cancer Genome Atlas Skin Cutaneous Melanoma 1 0.187 1.8
The Cancer Genome Atlas Stomach Adenocarcinoma 5 0.297 1.8
The Cancer Genome Atlas Testicular Germ Cell Tumors 1 0.078 1.7
The Cancer Genome Atlas Thyroid Carcinoma 10 0.194 1.7
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 2 0.394 1.6